|
|||
|
Home > News : Publications | ||
|
|||
|
|
|
|
Publications
Positive results in inflammatory eye disease treatment
http://www.swissbiotech.org/news/xigen%E2%80%99s-brimapitide-innovative-jnk-inhibitor-delivers-positive-phase-ii-results-inflammatory
https://scrip.pharmamedtechbi.com/SC097980/Xigens-PhII-Success-In-Ocular-Inflammation-Opens-Doors
Xigen’s Brimapitide, an innovative JNK inhibitor, delivers positive Phase II results in inflammatory eye disease. (PDF, 268 Kb)
https://scrip.pharmamedtechbi.com/SC097980/Xigens-PhII-Success-In-Ocular-Inflammation-Opens-Doors
Xigen’s Brimapitide, an innovative JNK inhibitor, delivers positive Phase II results in inflammatory eye disease. (PDF, 268 Kb)
Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness
ZUG, Switzerland, Sept. 9, 2016 (GLOBE NEWSWIRE)
Dual kinase inhibition affords extended in vitro neuroprotection in Aβ toxicity
Gourmaud et al, Journal of Alzheimer’s Disease, 2016, PMID: 27636848
The present study show that PKR (double-stranded RNA dependent kinase) and c-Jun N-terminal kinase (JNK) pathways are actively activated in Aβ-induced neurotoxicity in neuronal cultures and that the dual inhibition of PKR and JNK (using XG-102 and XG-104) nearly completely blocked neuronal death in vitro.
https://www.ncbi.nlm.nih.gov/pubmed/27636848
The present study show that PKR (double-stranded RNA dependent kinase) and c-Jun N-terminal kinase (JNK) pathways are actively activated in Aβ-induced neurotoxicity in neuronal cultures and that the dual inhibition of PKR and JNK (using XG-102 and XG-104) nearly completely blocked neuronal death in vitro.
https://www.ncbi.nlm.nih.gov/pubmed/27636848
Sub-conjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: A safety and tolerability study
Beydoun et al, Journal of Ocular Pharmacology and Therapeutics, 2015, PMID: 25347151
In this clinical trial, XG-102 administered as a single subconjunctival injection as adjunct therapy in patients with recent post-surgery or post-trauma intraocular inflammation is safe and well tolerated.
Complete version (PDF, 188 Kb)
In this clinical trial, XG-102 administered as a single subconjunctival injection as adjunct therapy in patients with recent post-surgery or post-trauma intraocular inflammation is safe and well tolerated.
Complete version (PDF, 188 Kb)
XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study
Deloche et al, Pharmacology Research & Perspectives, 2014, PMID: 25505576
The present clinical trial concluded that XG-102 single IV doses of 10-80 μg/kg administered over 1 h to healthy male subjects were safe and well tolerated.
Complete version (PDF, 832 Kb)
The present clinical trial concluded that XG-102 single IV doses of 10-80 μg/kg administered over 1 h to healthy male subjects were safe and well tolerated.
Complete version (PDF, 832 Kb)
Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study
Suckfuell et al, Otology Neurology, 2014, PMID: 24979398
The clinical study established proof of concept for AM-111 in the treatment of severe-to-profound acute sensorineural hearing loss (ASNHL). Control for spontaneous hearing recovery is essential for ASNHL studies
https://www.ncbi.nlm.nih.gov/pubmed/24979398
The clinical study established proof of concept for AM-111 in the treatment of severe-to-profound acute sensorineural hearing loss (ASNHL). Control for spontaneous hearing recovery is essential for ASNHL studies
https://www.ncbi.nlm.nih.gov/pubmed/24979398
Sub-conjunctival injection of XG-102, a c-Jun N-Terminal Kinase inhibitor peptide in the treatment of endotoxin-induced uveitis in rats
El Zaoui et al, Journal of Ocular Pharmacology and Therapeutics, 2014, PMID: 25313830
The study determined optimal XG-102 dose and route of administration in endotoxin-induced uveitis (EIU) in rats with the purpose of clinical study design. The results confirm that XG-102 peptide has potential for treating intraocular inflammation. Sub-conjunctival injection appears as a good compromise to provide a therapeutic effect while limiting side effects.
Complete version (PDF, 499 Kb)
The study determined optimal XG-102 dose and route of administration in endotoxin-induced uveitis (EIU) in rats with the purpose of clinical study design. The results confirm that XG-102 peptide has potential for treating intraocular inflammation. Sub-conjunctival injection appears as a good compromise to provide a therapeutic effect while limiting side effects.
Complete version (PDF, 499 Kb)
Molecular mechanisms involved in cochlear implantation trauma and the protection of hearing and auditory sensory cells by inhibition of c-Jun-N-terminal kinase signaling
Eshraghi et al, Laryngoscope, 2013, PMID: 23382052
Molecular mechanisms involved in programmed cell death of hair cells [HCs] are different than the ones involved in programmed cell death of supporting cells [SCs]. Local delivery of AM-111 provided a significant level of protection against electrode insertion trauma [EIT]-induced hearing losses, HC losses, and damage to neural elements.
Molecular mechanisms involved in programmed cell death of hair cells [HCs] are different than the ones involved in programmed cell death of supporting cells [SCs]. Local delivery of AM-111 provided a significant level of protection against electrode insertion trauma [EIT]-induced hearing losses, HC losses, and damage to neural elements.
Protection against ischemic cochlear damage by intratympanic administration of AM-111
Omotehara et al, Otology Neurology, 2011, PMID: 22089955
Direct application of AM-111 in gel formulation on the round window was effective in preventing acute hearing loss because of transient cochlear ischemia.
https://www.ncbi.nlm.nih.gov/pubmed/22089955
Direct application of AM-111 in gel formulation on the round window was effective in preventing acute hearing loss because of transient cochlear ischemia.
https://www.ncbi.nlm.nih.gov/pubmed/22089955
Auris Medical secures CHF 47.1 mn Series C financing from Sofinnova Ventures and Sofinnova Partners to advance ground-breaking inner ear therapies through Phase III clinical development
D-JNKI-1 treatment prevents the progression of hearing loss in a model of cochlear implantation trauma
Eshraghi et al, Otology Neurology, 2006, PMID: 16791042
Hearing loss caused by cochlear implant electrode insertion trauma in guinea pigs has both acute and delayed components. The delayed component can be prevented by treating the cochlea with D-JNKI-1.
https://www.ncbi.nlm.nih.gov/pubmed/16791042
Hearing loss caused by cochlear implant electrode insertion trauma in guinea pigs has both acute and delayed components. The delayed component can be prevented by treating the cochlea with D-JNKI-1.
https://www.ncbi.nlm.nih.gov/pubmed/16791042
